Syndax Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Syndax Pharmaceuticals's estimated annual revenue is currently $13.5M per year.
- Syndax Pharmaceuticals's estimated revenue per employee is $57,489
- Syndax Pharmaceuticals's total funding is $195M.
- Syndax Pharmaceuticals's current valuation is $976.3M. (January 2022)
Employee Data
- Syndax Pharmaceuticals has 235 Employees.
- Syndax Pharmaceuticals grew their employee count by 63% last year.
Syndax Pharmaceuticals's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Accounting Officer | Reveal Email/Phone |
2 | VP | VP | Marketing | Sales | Training | Reveal Email/Phone |
3 | Chief Commercial Officer | Reveal Email/Phone |
4 | Chief People Officer | Reveal Email/Phone |
5 | Chief Commercial Officer (CCO) | Reveal Email/Phone |
6 | VP Clinical Operations | Reveal Email/Phone |
7 | Head Market Analytics and Insights, | Reveal Email/Phone |
8 | Head Payer Relations | Reveal Email/Phone |
9 | VP Information Technology | Reveal Email/Phone |
10 | General Counsel and Secretary | Reveal Email/Phone |
Syndax Pharmaceuticals Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Syndax Pharmaceuticals?
Syndax Pharmaceuticals, Inc., was founded in 2005 to extend and improve the lives of cancer patients by developing and commercializing novel therapies. Our vision is bold—to modify the tumor phenotype, allowing for new therapeutic opportunities that restore or extend the benefit of targeted therapies. Our vision is practical—to develop effective regimens that have broad commercial potential by optimizing features important to patients, physicians, and payers.
keywords:N/A
$195M
Total Funding
235
Number of Employees
$13.5M
Revenue (est)
63%
Employee Growth %
$976.3M
Valuation
N/A
Accelerator
Syndax Pharmaceuticals News
Syndax Pharmaceuticals has higher revenue and earnings than ProMetic Life Sciences. Insider & Institutional Ownership. 0.1% of ProMetic Life...
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of Buy by Analysts. Posted by admin on Apr 18th, 2022.
Syndax Pharmaceuticals (NASDAQ:SNDX) shares appear to be under accumulation with sellers stepping back, and several cash raises have left...
Syndax Pharmaceuticals Inc., a Waltham, Massachusetts-based biopharmaceutical company focused on treating cancer, closed $80m in Series C funding. The round was led by Fidelity Management & Research Company and Delos Capital Fund LP led with participation from EcoR1 Capital, OrbiMed, Jennison A ...
WALTHAM, Mass., August 24, 2015 – Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications, announced today that it has completed an $80 million Series C financing. The financing was led by Fidelity ...
Other Companies in Waltham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $58.3M | 241 | 20% | N/A |
#2 | $15M | 253 | 12% | N/A |
#3 | $72.4M | 259 | -15% | N/A |
#4 | $39.9M | 259 | 5% | N/A |
#5 | $52.7M | 266 | N/A | N/A |